French Agency for the Health Safety of Health Products
Indications for use of labile blood products and the physiology of blood transfusion in medicine. The French Agency for the Health Safety of Health Products
Abstract
This article presents the French national recommendations for the use of blood products in medicine.
Source and rights
Published by Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine, 2005. The guideline itself is at the source linked here.
Prognia summarises this guideline for reference and education. It is not medical advice. Always check the official guideline and current local protocols before acting on it.
At a glance
- Organisation
- French Agency for the Health Safety of Health Products
- Published
- 2005
- Applies to
- 🇫🇷 France
- Scope
- National
- Journal
- Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine
- PubMed
- 15894502
- Added to Prognia
- 23 July 2026
More in haematology
- Perceived relative clinical significance of the risks of venous thromboembolism and bleeding from pharmacologic thromboprophylaxis in children: an international survey of pediatric providers: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and HemostasisInternational Society on Thrombosis and Haemostasis · 2026
- Evidence-based AGIHO guideline update on prophylaxis of infectious complications with granulocyte-stimulating factors (G-CSF) for the treatment of adult patients with cancerInfectious Diseases Working Party (AGIHO) of the German Society of Hematology and Medical Oncology (DGHO) · 2026
